Core Viewpoint - The announcement highlights the results of multiple clinical trials for various cardiovascular systems developed by the company, showcasing advancements in minimally invasive heart valve procedures [1] Group 1: Clinical Trial Results - The TRINITY trial results for the LuX-Valve Plus system, focusing on transcatheter tricuspid valve replacement (TTVR), were presented, emphasizing the six-month follow-up outcomes [1] - The one-year follow-up results for the JensClip system, which is designed for transcatheter mitral valve repair (TMVr), were also shared, along with insights on challenging case applications [1] - Additionally, the one-year follow-up results for the Ken-Valve system, used for transcatheter aortic valve replacement (TAVR), were discussed, including its performance in challenging cases [1] Group 2: Event Details - The results were presented at the TCT 2025 conference held in San Francisco, indicating the company's active participation in significant cardiovascular academic events [1]
健世科技-B(09877)多产品组合LuX-Valve Plus TRINITY研究、JensClip及 Ken-Valve临床效果于美国TCT 2025发布，成果瞩目